| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.19▲ | 3.17▲ | 3.17▲ | 3.19▲ | 3.16▲ |
| MA10 | 3.19▲ | 3.23▲ | 3.23▲ | 3.10▲ | 3.12▲ |
| MA20 | 3.24▲ | 3.25▲ | 3.23▲ | 3.11▲ | 2.85▲ |
| MA50 | 3.25▲ | 3.12▲ | 3.06▲ | 3.08▲ | N/A |
| MA100 | 3.14▲ | 3.05▲ | 3.12▲ | 2.80▲ | N/A |
| MA200 | 3.09▲ | 3.10▲ | 3.05▲ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.015▼ | -0.013▼ | 0.018▲ | 0.101▲ |
| RSI | 54.562▲ | 54.967▲ | 55.844▲ | 56.238▲ | 55.210▲ |
| STOCH | 56.250 | 44.326 | 52.470 | 66.576 | 48.878 |
| WILL %R | -5.556▲ | -8.108▲ | -20.930▲ | -23.333▲ | -41.968 |
| CCI | 63.900 | 37.978 | 41.440 | 96.668 | 68.183 |
|
Wednesday, August 13, 2025 01:34 PM
GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported first quarter fiscal year 2026 results highlighting the recent submission of its new drug application (NDA) for ...
|
|
Tuesday, August 12, 2025 05:13 AM
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 3.18 | 3.30 | 3.13 | 3.26 | 78,700 |
| 14/08/25 | 3.30 | 3.399 | 2.93 | 3.08 | 185,728 |
| 13/08/25 | 3.19 | 3.40 | 3.15 | 3.28 | 132,000 |
| 12/08/25 | 3.09 | 3.33 | 3.09 | 3.21 | 103,400 |
| 11/08/25 | 3.28 | 3.32 | 3.07 | 3.10 | 75,500 |
| 08/08/25 | 3.05 | 3.37 | 2.875 | 3.22 | 171,916 |
| 07/08/25 | 3.00 | 3.05 | 2.85 | 2.95 | 40,200 |
| 06/08/25 | 3.01 | 3.0197 | 2.89 | 2.97 | 52,293 |
| 05/08/25 | 3.00 | 3.00 | 2.895 | 2.965 | 40,771 |
| 04/08/25 | 2.95 | 3.01 | 2.80 | 3.00 | 122,130 |
|
|
||||
|
|
||||
|
|